NLRP3 and colitis: Furthermore, DCL exhibited protective effects in mouse models of NLRP3 inflammasome‐mediated diseases, including dextran sulfate sodium‐induced colitis, 2,4,6‐trinitrobenzenesulfonic acid‐induced Crohn's disease, LPS‐induced septic shock, and monosodium urate‐induced peritonitis.